Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland
Haemophilia · 2025
DOI: 10.1111/hae.70067 ↗Kurz gefasst
Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Mirkka Koivusalo und 12 weiteren Autor:innen. Beteiligte Einrichtung: MedEngine Oy, Helsinki, Finland. Hauptthemen laut MEDLINE: Hemophilia A, Blood Coagulation Factors, Health Care Costs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Pharma.
Abstract (Originalsprache)
Introduction
Real‐world data are needed to evaluate treatment implementation, outcomes and costs of care in haemophilia patients switching prophylaxis from standard half‐life (SHL) to extended half‐life (EHL) clotting factor concentrates (CFCs).
Aim
We characterised treatment regimens, annual bleeding rate (ABR), adherence and costs in a nationwide Finnish haemophilia A (HA) and B (HB) cohort on prophylaxis, including non‐switchers and switchers from SHL to EHL CFC.
Methods
This retrospective register study of adult patients with HA and HB was performed in University Hospitals during 2016–2021. Clinical and healthcare data were captured from electronic health records and national healthcare registers.
Results
Majority, 74% of HA and 71% of HB patients, switched from SHL to EHL. Thereafter, weekly mean infusions of CFC decreased (FVIII SHL 2.8, EHL 2.2; FIX SHL 1.6, EHL 0.9; p < 0.001). The mean annual consumption (international units, IU) increased by 18% from 219,534 per HA patient during SHL to 258,317 during EHL ( p < 0.05) and declined per HB patient by 28% from 221,685 to 160,209 ( p < 0.01). ABR appeared to decline after the switch in HA (mean SHL 2.8, EHL 0.9) and HB (SHL 1.6, EHL 0.8), while treatment adherence improved in HA from 81% to 95% ( p < 0.01). The mean annual total costs of care in HA were €176,979 for SHL and €195,760 for EHL. In HB, the costs increased from €180,930 to €236,208 ( p < 0.01).
Conclusions
Majority of patients on prophylaxis switched to EHL. The switch alleviated the infusion regimen, tended to lower bleeding rates and improved adherence with somewhat increased costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MedEngine Oy, Helsinki, Finland.
- Department of Hematology, Comprehensive Cancer Center, Coagulation Disorders Unit, Helsinki University Hospital, Helsinki, Finland.
- Research Program Unit in Systems Oncology, University of Helsinki, Helsinki, Finland.
- Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
- Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
- Department of Medicine, Oulu University Hospital, Oulu, Finland.
ORCID-Profile: Timea Szanto, Aino Vesikansa, Riitta Lassila
Förderung
- Novo Nordisk Pharma
Zitieren
APA
Koivusalo, M., Szanto, T., Kovalainen, T., Vesikansa, A., Laine, O., Partanen, A., Siitonen, T., Vesanen, M., Mehtälä, J., Sarnesto, N., Haapkylä, J., Lehtinen, A. E., & Lassila, R. (2025). Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland. Haemophilia. https://doi.org/10.1111/hae.70067
Vancouver
Koivusalo M, Szanto T, Kovalainen T, Vesikansa A, Laine O, Partanen A, et al. Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland. Haemophilia. 2025. doi:10.1111/hae.70067
BibTeX
@article{Koivusalo2025,
author = {Koivusalo, Mirkka and Szanto, Timea and Kovalainen, Tuomas and Vesikansa, Aino and Laine, Outi and Partanen, Anu and Siitonen, Timo and Vesanen, Marko and Mehtälä, Juha and Sarnesto, Nina and Haapkylä, Johanna and Lehtinen, Anna-Elina and Lassila, Riitta},
title = {Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland},
journal = {Haemophilia},
year = {2025},
doi = {10.1111/hae.70067}
}
EUVIMED